Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for Non-alcoholic Fatty Liver Disease
NCT02283710Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pentoxifylline in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Change from baseline serum alanine aminotransferase at 6 months. Started May 2013; status: completed.
02
Drugs
pentoxifylline
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02283710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283710.